Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study

https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(23)00243-0/fulltext?dgcid=hubspot_update_feature_updatealerts_lanhae&utm_campaign=update-lanhae&utm_medium=email&_hsmi=278408633&_hsenc=p2ANqtz--x6omZF5yvaaI3YuX5CBcW014GS7CBvR_uF1gW3d1f3-VV_oXbgJ3PH-7yI9uBkoPxFzhwGCRFMfzl0p7LdLp9Vu_cSw&utm_content=278217566&utm_source=hs_email